Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia
Author: Sutton, R.
Shaw, P.
Venn, N.
Law, T.
Dissanayake, A.
Kilo, T.
Haber, M.
Norris, M.
Fraser, C.
Alvaro, F.
Revesz, T.
Trahair, T.
Dalla-Pozza, L.
Marshall, G.
O'Brien, T.
Citation: British Journal of Haematology, 2015; 168(3):395-404
Publisher: Wiley
Issue Date: 2015
ISSN: 0007-1048
Statement of
Rosemary Sutton, Peter J. Shaw, Nicola C. Venn, Tamara Law, Anuruddhika Dissanayake, Tatjana Kilo, Michelle Haber, Murray D. Norris, Chris Fraser, Frank Alvaro, Tamas Revesz, Toby N. Trahair, Luciano Dalla-Pozza, Glenn M. Marshall, and Tracey A. O’Brien
Abstract: Minimal residual disease (MRD) during early chemotherapy is a powerful predictor of relapse in acute lymphoblastic leukaemia (ALL) and is used in children to determine eligibility for allogeneic haematopoietic stem cell transplantation (HSCT) in first (CR1) or later complete remission (CR2/CR3). Variables affecting HSCT outcome were analysed in 81 children from the ANZCHOG ALL8 trial. The major cause of treatment failure was relapse, with a cumulative incidence of relapse at 5 years (CIR) of 32% and treatment-related mortality of 8%. Leukaemia-free survival (LFS) and overall survival (OS) were similar for HSCT in CR1 (LFS 62%, OS 83%, n = 41) or CR2/CR3 (LFS 60%, OS 72%, n = 40). Patients achieving bone marrow MRD negativity pre-HSCT had better outcomes (LFS 83%, OS 92%) than those with persistent MRD pre-HSCT (LFS 41%, OS 64%, P < 0·0001) or post-HSCT (LFS 35%, OS 55%, P < 0·0001). Patients with B-other ALL had more relapses (CIR 50%, LFS 41%) than T-ALL and the main precursor-B subtypes including BCR-ABL1, KMT2A (MLL), ETV6-RUNX1 (TEL-AML1) and hyperdiploidy >50. A Cox multivariate regression model for LFS retained both B-other ALL subtype (hazard ratio 4·1, P = 0·0062) and MRD persistence post-HSCT (hazard ratio 3·9, P = 0·0070) as independent adverse prognostic variables. Persistent MRD could be used to direct post-HSCT therapy.
Keywords: Acute lymphoblastic leukaemia; minimal residual disease; bone marrow transplantation; IKZF1; childhood leukaemia
Rights: © 2014 John Wiley & Sons Ltd
RMID: 0030028312
DOI: 10.1111/bjh.13142
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.